Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

计划入组 15 人 · 首次发布于 2017 年 4 月 14 日

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

计划入组 11 人 · 首次发布于 2018 年 4 月 30 日

Study of Factors of Genetic Susceptibility Associated to Severe Caries Phenotype

计划入组 390 人 · 首次发布于 2007 年 10 月 8 日

Correction of Q347X mutation(Beam Therapeutics)

KRAS mutation G12D-targeted ONCOlogues ( Oncogenuity)

Personalized Mutation-derived Tumor Vaccine(NovoCure)

Cogent Biosciences

United States

Nuvation Bio

United States

FONDS DE DOTATION HTC PROJECT

France

Nippon Shinyaku Exercises Option for AB2 Bio's Tadekinig Alfa, Securing U.S. Commercialization Rights for Rare Autoinflammatory Diseases

AB2 Bio and Nippon Shinyaku Strike $686M Deal for Rare Disease Drug Tadekinig Alfa

Nippon Shinyaku Exercises $30 Million U.S. Commercialization Option for AB2 Bio's Tadekinig Alfa in Ultra-Rare Pediatric Hyperinflammatory Syndrome